BCR-ABL Translocation by RT-PCR, Quantitative, Blood
The BCR/ABL quantitative assay by RT-PCR is designed to detect and quantify expression of the BCR/ABL fusion gene t(9;22) from patient specimens. The BCR/ABL fusion gene is formed by reciprocal translocation t(9;22)(q34;q11), resulting in an abnormally short derivative chromosome 22 (22q-), which is known as the Philadelphia chromosome. At the molecular level, the translocation (gene rearrangement) results in fusion of BCR gene coding sequences to ABL gene coding sequences. The resultant chimeric gene and fusion transcript encode a fusion protein with constitutively activated tyrosine kinase activity, suggested to be responsible for the development of certain leukemias. Approximately 95% of cases of chronic myelogenous leukemia (CML) have the characteristic t(9;22)(q34;q11). The remaining cases either have an unidentifiable translocation between 9q34 and 22q11 that cannot be identified by routine cytogenetic analysis, or have variant translocations involving a third or even a fourth chromosome besides 9 and 22. A subset of acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) also have the Ph chromosome, and therefore are positive for bcr/abl, t(9;22) translocation.
This assay can also be used to distinguish between the major and minor transcripts. The major transcript, characterized by the p210 fusion gene product, is typically detected in CML. The minor transcript, characterized by the p190 fusion gene product, is typically detected in ALL. Small amounts of p190 transcript can be detected in the majority of patients with CML due to alternative splicing of the bcr gene.
- Diagnosis of chronic myelogenous leukemia
- Diagnosis (differentiation) of acute lymphoblastic leukemia with t(9;22) BCR/ABL rearrangement
- Determination of a baseline level of BCR/ABL fusion gene expression in newly diagnosed CML or ALL patients
- Monitor the effectiveness of therapy
- Monitor for molecular evidence of minimal residual disease (MRD)
- Monitor molecular remission in response to conventional chemotherapy, or allogeneic stem cell transplantation and monitor for early relapse
Positive in:
- 95% of chronic myelogenous leukemia (CML)
- Subsets of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
Not detected (Negative for bcr/abl)
Whole blood, EDTA (Lavender).
Stability
- Ambient – 1-3 days
- Refrigerated – 7 days
- Frozen - Unacceptable
3 to 10 days.
- Eur J Haematol. 2003 Jan;70(1):1-10. [PMID: 12631253]
- J Mol Diagn. 2003 May;5(2):63-72. [PMID: 12707370]
- Blood. 2006 Jul 1;108(1):28-37. [PMID: 16522812]
- Hematol Oncol. 2006 Dec;24(4):196-204. [PMID: 16988930]
- Ann Intern Med. 2003 May 20;138(10):819-30. [PMID: 12755554]
- Clin Cancer Res. 2003;9:160. [PMID: 12538464]
- Cancer Genet Cytogenet. 2006;166:89. [PMID: 16616117]
- Ann Int Med. 2006;145:913. [PMID: 17179059]